These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

109 related items for PubMed ID: 15255557

  • 1. Clinical experience with levofloxacin in the treatment of pneumonia in ICU patients.
    Alvarez Lerma F, Study Group of Levofloxacin Use in the ICU.
    J Chemother; 2004 Apr; 16 Suppl 2():15-7. PubMed ID: 15255557
    [No Abstract] [Full Text] [Related]

  • 2. A comparison of levofloxacin and moxifloxacin use in hospitalized community-acquired pneumonia (CAP) patients in the US: focus on length of stay.
    Schein J, Janagap-Benson C, Grant R, Sikirica V, Doshi D, Olson W.
    Curr Med Res Opin; 2008 Mar; 24(3):895-906. PubMed ID: 18419876
    [Abstract] [Full Text] [Related]

  • 3. Does de-escalation of antibiotic therapy for ventilator-associated pneumonia affect the likelihood of recurrent pneumonia or mortality in critically ill surgical patients?
    Eachempati SR, Hydo LJ, Shou J, Barie PS.
    J Trauma; 2009 May; 66(5):1343-8. PubMed ID: 19430237
    [Abstract] [Full Text] [Related]

  • 4. Levofloxacin PK/PD: from sequential therapy model to high dosage for critical patients.
    Pea F, Furlanut M.
    J Chemother; 2004 Apr; 16 Suppl 2():8-10. PubMed ID: 15255555
    [No Abstract] [Full Text] [Related]

  • 5. High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm.
    Dunbar LM, Wunderink RG, Habib MP, Smith LG, Tennenberg AM, Khashab MM, Wiesinger BA, Xiang JX, Zadeikis N, Kahn JB.
    Clin Infect Dis; 2003 Sep 15; 37(6):752-60. PubMed ID: 12955634
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Safety and efficacy of intravenous tigecycline in treatment of community-acquired pneumonia: results from a double-blind randomized phase 3 comparison study with levofloxacin.
    Bergallo C, Jasovich A, Teglia O, Oliva ME, Lentnek A, de Wouters L, Zlocowski JC, Dukart G, Cooper A, Mallick R, 308 Study Group.
    Diagn Microbiol Infect Dis; 2009 Jan 15; 63(1):52-61. PubMed ID: 18990531
    [Abstract] [Full Text] [Related]

  • 11. Levofloxacin 750-mg for 5 days for the treatment of hospitalized Fine Risk Class III/IV community-acquired pneumonia patients.
    Shorr AF, Khashab MM, Xiang JX, Tennenberg AM, Kahn JB.
    Respir Med; 2006 Dec 15; 100(12):2129-36. PubMed ID: 16730170
    [Abstract] [Full Text] [Related]

  • 12. Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia: the MOTIV study--a randomized clinical trial.
    Torres A, Garau J, Arvis P, Carlet J, Choudhri S, Kureishi A, Le Berre MA, Lode H, Winter J, Read RC, MOTIV (MOxifloxacin Treatment IV) Study Group.
    Clin Infect Dis; 2008 May 15; 46(10):1499-509. PubMed ID: 18419482
    [Abstract] [Full Text] [Related]

  • 13. Clinical implications of 750 mg, 5-day levofloxacin for the treatment of community-acquired pneumonia.
    File TM, Milkovich G, Tennenberg AM, Xiang JX, Khashab MM, Zadeikis N.
    Curr Med Res Opin; 2004 Sep 15; 20(9):1473-81. PubMed ID: 15383197
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Treatment failure rates and health care utilization and costs among patients with community-acquired pneumonia treated with levofloxacin or macrolides in an outpatient setting: a retrospective claims database analysis.
    Ye X, Sikirica V, Schein JR, Grant R, Zarotsky V, Doshi D, Benson CJ, Riedel AA.
    Clin Ther; 2008 Feb 15; 30(2):358-71. PubMed ID: 18343274
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Alternative anti-tuberculosis regimen including ofloxacin for the treatment of patients with hepatic injury.
    Szklo A, Mello FC, Guerra RL, Dorman SE, Muzy-de-Souza GR, Conde MB.
    Int J Tuberc Lung Dis; 2007 Jul 15; 11(7):775-80. PubMed ID: 17609053
    [Abstract] [Full Text] [Related]

  • 18. Increased insulin requirements are associated with pneumonia after severe injury.
    Martin RS, Smith JS, Hoth JJ, Miller PR, Meredith JW, Chang MC.
    J Trauma; 2007 Aug 15; 63(2):358-64. PubMed ID: 17693836
    [Abstract] [Full Text] [Related]

  • 19. Pneumonia due to Pseudomonas aeruginosa: the levofloxacin clinical trials experience.
    Tennenberg AM, Davis NB, Wu SC, Kahn J.
    Curr Med Res Opin; 2006 May 15; 22(5):843-50. PubMed ID: 16709306
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.